ValuEngine upgraded shares of T2 Biosystems (NASDAQ:TTOO) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday morning.
Several other equities analysts have also recently commented on the stock. HC Wainwright set a $8.00 price target on shares of T2 Biosystems and gave the company a buy rating in a report on Wednesday, March 7th. Goldman Sachs Group began coverage on shares of T2 Biosystems in a report on Monday, January 29th. They set a neutral rating and a $5.20 price target on the stock. Finally, Zacks Investment Research cut shares of T2 Biosystems from a buy rating to a hold rating in a report on Saturday, January 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $5.56.
T2 Biosystems (TTOO) opened at $6.85 on Tuesday. The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.28 and a current ratio of 5.40. T2 Biosystems has a fifty-two week low of $2.50 and a fifty-two week high of $7.26. The company has a market cap of $252.62, a price-to-earnings ratio of -3.59 and a beta of 1.49.
Several institutional investors have recently bought and sold shares of TTOO. Renaissance Technologies LLC boosted its holdings in T2 Biosystems by 72.2% in the fourth quarter. Renaissance Technologies LLC now owns 83,500 shares of the medical equipment provider’s stock worth $344,000 after purchasing an additional 35,000 shares in the last quarter. Gagnon Securities LLC bought a new stake in T2 Biosystems in the third quarter worth $396,000. Geode Capital Management LLC boosted its holdings in T2 Biosystems by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 134,470 shares of the medical equipment provider’s stock worth $554,000 after purchasing an additional 39,722 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in T2 Biosystems in the third quarter worth $630,000. Finally, Lagoda Investment Management L.P. boosted its holdings in T2 Biosystems by 61.4% in the third quarter. Lagoda Investment Management L.P. now owns 3,188,539 shares of the medical equipment provider’s stock worth $13,392,000 after purchasing an additional 1,212,618 shares in the last quarter. Institutional investors and hedge funds own 52.61% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Upgrades T2 Biosystems (TTOO) to “Sell”” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/14/valuengine-upgrades-t2-biosystems-ttoo-to-sell.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.